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Abstract
Prolonged heavy exposure to cannabis is associated with impaired cognition and brain functional and
structural alterations. We recently reported attenuated mismatch negativity (MMN) and altered P50 sensory
gating in chronic cannabis users. This study investigated the extent of brain functional recovery (indexed by
MMN and P50) in chronic users after cessation of use. Eighteen ex-users (median 13.5 years prior regular use;
median 3.5 years abstinence) and 18 nonusers completed (1) a multifeature oddball task with duration,
frequency, and intensity deviants and (2) a P50 paired-click paradigm. Trend level smaller duration MMN
amplitude and larger P50 ratios (indicative of poorer sensory gating) were observed in ex-users compared to
controls. Poorer P50 gating correlated with prior duration of cannabis use. Duration of abstinence was
positively correlated with duration MMN amplitude, even after controlling for age and duration of cannabis
use. Impaired sensory gating and attenuated MMN amplitude tended to persist in ex-users after prolonged
cessation of use, suggesting a lack of full recovery. An association with prolonged duration of prior cannabis
use may indicate persistent cannabis-related alterations to P50 sensory gating. Greater reductions in MMN
amplitude with increasing abstinence (positive correlation) may be related to either self-medication or an
accelerated aging process.
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Prolonged heavy exposure to cannabis is associated with impaired cognition and brain functional and structural alterations. We
recently reported attenuated mismatch negativity (MMN) and altered P50 sensory gating in chronic cannabis users. This study
investigated the extent of brain functional recovery (indexed by MMN and P50) in chronic users after cessation of use. Eighteen
ex-users (median 13.5 years prior regular use; median 3.5 years abstinence) and 18 nonusers completed (1) a multifeature oddball
task with duration, frequency, and intensity deviants and (2) a P50 paired-click paradigm. Trend level smaller duration MMN
amplitude and larger P50 ratios (indicative of poorer sensory gating) were observed in ex-users compared to controls. Poorer
P50 gating correlated with prior duration of cannabis use. Duration of abstinence was positively correlated with duration MMN
amplitude, even after controlling for age and duration of cannabis use. Impaired sensory gating and attenuated MMN amplitude
tended to persist in ex-users after prolonged cessation of use, suggesting a lack of full recovery. An association with prolonged
duration of prior cannabis use may indicate persistent cannabis-related alterations to P50 sensory gating. Greater reductions in
MMN amplitude with increasing abstinence (positive correlation) may be related to either self-medication or an accelerated aging
process.
1. Introduction
Regular and prolonged cannabis use is associated with a
range of adverse psychological outcomes, including psy-
chosis [1–4]. The primary constituent of cannabis, Δ9-
tetrahydrocannabinol (THC), is a partial agonist at central
cannabinoid receptor (CB1R) sites which are densely located
throughout the brain but especially within regions critical to
attention, learning, and memory, such as the hippocampus,
amygdala, and prefrontal cortex [5]. It is these cognitive
functions in particular that are impaired in cannabis users
(for a review, see [6]), arguably due to cannabis-related
alterations to the regulatory role that the endocannabinoid
system plays in synaptic plasticity [7–10].The latter is thought
to occur, at least in part, via downregulation of N-methyl-
D-aspartate (NMDA) receptor activity [7–9, 11]. Evidence
is also emerging for analogous alterations in cannabis users
and patients with schizophrenia, including cognition, brain
function, and structure, and there is increasing support
for an association between cannabis and schizophrenia in
vulnerable individuals [12–14]. In light of this evidence,
research has turned to examining common neurobiological




Volume 2016, Article ID 6526437, 11 pages
http://dx.doi.org/10.1155/2016/6526437
2 Neural Plasticity
Two such candidate markers are the mismatch negativity
(MMN) and the P50, event-related potential (ERP) brain
markers of early sensory memory and of sensory gating,
respectively. MMN is sensitive to NMDA receptor function
(for a review, see [15, 16]) and elicited by irregular acoustic
deviations (“deviants”) in a predictable pattern of auditory
stimuli (called standards [17, 18]) reflecting evaluation of new
auditory sensory input against current models of the acoustic
environment [18]. Robust reductions in MMN have been
noted in patients with schizophrenia [19, 20] and less consis-
tently in their first degree relatives [21–23]. Cannabis users
also show reduced MMN, with the strongest evidence for
alterations to frequency deviants [24–26], but three studies
have also reported group differences for duration deviants
[24, 27, 28]. We recently reported significantly smaller
frequency MMN in both long-term and short-term users
compared to controls, whereas duration MMN was reduced
only in long-term users, and duration MMN amplitude
reduction was associated with the duration of regular and, in
particular, daily cannabis use [24]. Consistent with mounting
evidence of an association between cannabis use and risk
for psychosis, reductions in duration and frequency MMN
were associated with a retrospective measure of psychotic-
like symptoms during intoxication [24].
P50 sensory gating is also impaired in both patients with
schizophrenia [29, 30] and chronic cannabis users [31–34].
Sensory gating refers to the brain’s ability to regulate its
response to incoming stimuli [35] or to “gate out” irrele-
vant information from further processing [36–38]. (Sensory
gating-“out”may be contrastedwith the brain’s ability to “gate
in” novel or new information, of which theMMN is a marker
[36, 37].) P50 sensory gating is impaired in regular cannabis
users compared to both nonuser controls [31–34] and patients
with schizophrenia with and without comorbid cannabis use
[33]. Longer duration of use [33] and greater quantity of
monthly use [32] were associated with more pronounced P50
gating impairments.
The existence of brain alterations in cannabis users leads
to the important question of whether these are amenable to
recovery following cessation of cannabis use. Persistent IQ
decline has been reported in adult cannabis users who started
using cannabis during adolescence and who had recently
abstained or significantly reduced cannabis use for at least one
year [39]. Results from more sensitive neuroimaging studies
of users with at least 25 days abstinence indicate persistent
alterations to brain function [40–46].We previously reported
impaired ERPmeasures of selective attention in former users
with amean 2-year abstinence thatwere associatedwith dura-
tion of prior use [47]. Pertinent to the current study, Rentzsch
et al. [33] identified persistent deficits in P50 sensory gating
in cannabis users who had been abstinent for at least 28
days and in a subsequent study [25] persistent reductions in
frequency MMN amplitude in former users with a mean 19-
month abstinence. Neither study investigated the association
between duration of abstinence or prior cannabis use and
recovery of brain function.Therefore, although these findings
suggest persistent cannabis-related alterations to MMN and
P50 sensory gating following cessation of cannabis use,
further research is required to replicate these findings and
determine the degree to which recovery may occur as a
function of prior cannabis exposure and length of abstinence.
The aim of the current cross-sectional study, in which we
recruited former cannabis users with a range of abstinence
and prior history of use, was to investigate (1)whetherMMN
amplitude and P50 sensory gating improve as a function
of increasing periods of abstinence following cessation of
use and (2) the extent to which recovery may depend on
the degree of prior cannabis use. Consistent with previous
work, we predicted that ex-users would exhibit attenuated
frequency and durationMMN (impaired sensory processing)
and larger P50 ratios and smaller P50 difference scores
(poorer sensory gating) compared to nonuser controls and
that improvement in brain function would be positively cor-
related with duration of abstinence and negatively correlated
with duration of prior cannabis use.
2. Materials and Methods
2.1. Participants. Twenty abstinent former cannabis users
and 42 healthy nonuser controls took part in the current
study. Ex-cannabis users were required to have used cannabis
regularly (≥3 times/week) for at least two years prior to
quitting and to have abstained for at least one month; two
were excluded for recent other drug use leaving a sample of
18 ex-users. Nonuser control participants were required to
have <20 lifetime occasions of cannabis use and none in the
previous 12 months. Recruitment and exclusion criteria are
described in Supplement 1 in Supplementary Material avail-
able online at http://dx.doi.org/10.1155/2016/6526437. Con-
trols were recruited as part of a larger study (see [24, 31]).
Whilst ex-users completed all experimental paradigms, not
all controls completed bothMMNandP50 paradigms.There-
fore, two overlapping subsamples (𝑛 = 18 each) of the most
appropriately age-matched controls were blindly selected
for MMN and P50 analyses, respectively, from the nonuser
sample reported in Greenwood et al. [24] (12 participants
were included in both control groups). All participants were
reimbursed AUD$50 for their participation. The study was
approved by the University of Wollongong and Illawarra
Shoalhaven LocalHealthDistrictHealth andMedicalHuman
Research Ethics Committee.
2.2. Demographic and Substance Use Variables. Participants
underwent a comprehensive structured interview to assess
demographic information, detailed history of current and
previous substance use, and psychiatric history and ex-users
provided a urine sample to verify recent abstinence. Partic-
ipants were excluded if they reported a personal or familial
(first degree relative) history of any psychotic disorder.
Participants reported (i) the last time they used any cannabis
and howmuch; (ii) their previous patterns of regular use (i.e.,
their usual pattern of use, periods when they used cannabis
more or less frequently, and periods of abstinence); and (iii)
when they stopped using cannabis regularly. This informed
two key variables to define the duration of abstinence: (i) time
since last use, defined in years since last use of any cannabis
and (ii) time since last regular use of cannabis (> once/month
for any 6-month period).
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The vocabulary and matrices subscales of the Wechsler
Abbreviated Scale of Intelligence (WASI [49]) were used to
estimate full scale IQ.The Rey Auditory Verbal Learning Test
(RAVLT) was also administered and participants completed
the Community Assessment of Psychic Experiences (CAPE
[50]) and Schizotypal PersonalityQuestionnaire (SPQ [51]) to
assess psychotic-like symptoms, the Beck Depression Inven-
tory (BDI [52]), State Trait Anxiety Inventory (STAI [53]),
Edinburgh Handedness Inventory [54], and the Alcohol
Use Disorders Identification Test (AUDIT [55]). Ex-cannabis
users also completed the Marijuana Withdrawal Checklist
(MWC [56]), Severity of Dependence Scale (SDS [57]),
and Cannabis Experiences Questionnaire (CEQ, [58]) to
measure symptoms of withdrawal and retrospective severity
of dependence and symptoms experiencedwhilst intoxicated.
2.3. Experimental Paradigms. ThepassivemultifeatureMMN
paradigm and recording conditions, with duration (100ms),
frequency (1200Hz), and intensity (90 dB; standards 50ms,
1000Hz, 80 dB) deviants, are described in Greenwood et
al. [24] and further in Supplement 1. For the MMN task
participants were instructed to ignore the tones and focus
their attention on a silent film. The attended P50 paired-
click paradigm (in which participants were asked to silently
count the click pairs and respond to every 25th click pair via
button press) and recording condition (ISI 9 seconds) were
identical to the paradigm described in Broyd et al. [31] and in
Supplement 1. Participants were seated in a comfortable chair
approximately 80 cmaway fromamonitor in a dimly lit room.
All stimuli were presented binaurally using headphones
(Sennheiser HD215). Measurement details of MMN and P50
are described in Supplement 1 and Greenwood et al. [24] and
Broyd et al. [31] respectively.
2.4. Statistical Analysis. To investigate potential group differ-
ences on demographic factors (age, gender, and IQ), psycho-
logical symptoms, verbal learning, and alcohol and tobacco
use, independent sample 𝑡-tests or Mann-Whitney 𝑈 tests
(for data not normally distributed) were employed. Group
comparisons of MMN peak amplitude were performed
using repeated measures Analysis of Variance (rmANOVA)
including a within-subject variable, condition (3: duration,
frequency, and intensity deviant), and between-subject factor,
group (2: control and ex-user). P50 ratio and difference scores
were compared between groups usingMann-Whitney𝑈 tests
as the data were not normally distributed. Correlational
analysis investigated associations between MMN and P50
measures, cannabis measures (duration of abstinence and of
prior use), and relevant demographic, clinical, and cognitive
measures in the ex-user sample. As prior research suggests
that frequency and duration MMN are reduced in cannabis
users in particular [24], correlations between MMN and
cannabis use history including duration of abstinence were
restricted to these deviant conditions.
3. Results
3.1. Cannabis Use History and Abstinence. Ex-users had
previously used cannabis regularly for a median of 13.5 years
Table 1: Cannabis use measures including abstinence, retrospective
measures of dependence and psychological symptoms during intox-
ication, and withdrawal symptoms.
Ex-cannabis users
Prior cannabis use
Frequency (days/month) 30 [15.0–30.0]
Quantity (conesa/month) 517.5 [52.5–3150.0]
Age of onset (years) 17 [12.0–20.5]
Duration of regular use (years) 13.5 [4.3–30.3]
Duration of daily use (months) 155.3 [0.0–363.7]
Time since last smoked (years) 1.5 [0.1–16.0]









Notes. Data are reported as median [range].
aCones used in waterpipe: 3 cones are equivalent to one standard sized joint
[48].
bSeverity of Dependence Scores (SDS) (retrospective)
cCannabis Experiences Questionnaire (CEQ) (retrospective)
dMarijuana Withdrawal Checklist (MWC) (retrospective).
at approximately 6 joints/day on a median of 30 days/month
(see Table 1). They had not used cannabis regularly for a
median of 3.5 years and had been totally abstinent (since
last occasion of any use) for a median of 1.5 years (range
of 6 weeks to 16 years for both measures of abstinence). No
participants had used any substance other than alcohol or
tobacco regularly (defined as more than once/month for a 6-
month period) in the past 5 years.
3.2. Group Comparisons on Demographic and Clinical Vari-
ables. No differences between ex-users and controls were
identified for age, gender, handedness, verbal learning (i.e.,
RAVLT performance), or symptom measures (Table 2) other
than the SPQ scores reported below.
MMN Group Comparisons. Ex-users had fewer years of
education (𝑍 = −3.64, 𝑝 < .001), tended to have lower
IQ (𝑍 = −1.80, 𝑝 = .073), consumed a greater quantity of
alcohol (𝑍 = −2.08, 𝑝 = .04) with a trend toward greater
frequency (𝑍 = −1.71, 𝑝 = .09), and smoked more cigarettes
than controls (𝑍 = −3.00, 𝑝 = .003). Ex-users had elevated
SPQ social anxiety (𝑍 = −2.03, 𝑝 = .04) and a trend toward
elevated SPQ total (𝑍 = −1.74, 𝑝 = .08) scores. None
of these variables were correlated with MMN amplitude in
any deviant condition and therefore none were included as
covariates in any further analyses (see Supplement 1).
P50 Group Comparisons. Ex-users tended to have lower IQ
scores (𝑍 = −1.87,𝑝 = .064) and had fewer years of education
(𝑍 = −3.92, 𝑝 < .001) than controls. They smoked more
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Table 2: Demographic, cognitive, and psychological symptom measures in ex-cannabis users and healthy nonuser controls for MMN and
P50 analyses.
Ex-cannabis users MMN controls P50 controls
(𝑛 = 18) (𝑛 = 18) (𝑛 = 18)
Age (years) 39.1 [20.8–56.0] 40.4 [21.0–52.6] 31.2 [20.1–52.6]
Gender (male/female) 10M/8 F 10M/8 F 9M/9 F
Handedness All right-handed Two left-handed All right-handed
Education (years) 12.0 [10.0–16.0] 14.3 [11.5–20.0]∗∗ 14.5 [11.5–20.0]∗∗
IQ 105.0 [89.0–126.0] 115.5 [89.0–133.0]/ 115.0 [89.0–133.0]/
RAVLT trials I to V 54.00 [34.0–68.0] 54.5 [29.0–69.0] 56.50 [29.0–70.0]
RAVLT trial VI 11.5 [5.0–15.0] 12.0 [4.0–15.0] 12.0 [4.0–15.0]
RAVLT trial VII 11.5 [0.0–15.0] 11.0 [3.0–15.0] 11.0 [3.0–15.0]
Alcohol frequencya 3.5 [0.0–30.0] 1.0 [0.0–12.0]/ 1.4 [0.0–12.0]
Alcohol quantityb 16.8 [0.0–180.0] 5.1 [0.0–28.0]∗ 6.3 [0.0–70.0]
Cigarettes (per day) 3.8 [0.0–35.0] 0.0 [0.0–12.0]∗ 0.0 [0.0–11.0]∗
Psychological symptoms
K10 15.0 [12.0–31.0] 14.0 [10.0–19.0] 14.0 [10.0–22.0]
BDI 6.5 [0.0–18.0] 3.0 [0.0–19.0] 3.0 [0.0–19.0]
STAI-I 31.0 [20.0–67.0] 32.0 [20.0–45.0] 27.5 [20.0–45.0]
STAI-II 39.0 [21.0–62.0] 36.0 [22.0–50.0] 32.5 [20.0–45.0]
CAPE
Frequency total 58.0 [46.0–76.0] 60.0 [46.0–89.0] 59.0 [47.0–89.0]
Distress total 20.0 [4.0–51.0] 25.5 [6.0–95.0] 22.0 [5.0–50.0]
Negative frequency 21.5 [16.0–35.0] 21.5 [12.0–31.0] 21.0 [15.0–31.0]
Negative distress 11.0 [2.0–30.0] 10.5 [2.0–41.0] 9.0 [2.0–22.0]
Positive frequency 23.5 [20.0–31.0] 25.0 [21.0–44.0] 26.0 [20.0–44.0]
Positive distress 5.5 [0.0–20.0] 6.0 [1.0–29.0] 6.0 [0.0–18.0]
Depressive frequency 12.5 [9.0–16.0] 13.0 [9.0–21.0] 12.0 [9.0–21.0]
Depressive distress 6.0 [2.0–15.0] 8.0 [2.0–25.0] 7.0 [1.0–21.0]
SPQ
Total 18.0 [9.0–32.0] 14.0 [5.0–32.0]/ 12.0 [2.0–39.0]/
Ideas of reference 1.0 [0.0–6.0] 1.0 [0.0–4.0] 1.0 [0.0–5.0]
Social anxiety 3.0 [0.0–15.0] 2.0 [0.0–6.0]∗ 1.0 [0.0–6.0]∗
Odd beliefs 1.0 [0.0–5.0] 0.0 [0.0–5.0] 0.0 [0.0–7.0]
Unusual perceptual 1.0 [0.0–3.0] 1.0 [0.0–2.0] 1.0 [0.0–4.0]
Odd behaviour 2.0 [0.0–5.0] 0.0 [0.0–6.0] 0.0 [0.0–6.0]
Close friends 2.0 [0.0–8.0] 1.0 [0.0–3.0] 1.0 [0.0–4.0]
Odd speech 4.0 [0.0–7.0] 4.0 [1.0–8.0] 3.0 [0.0–8.0]
Constricted affect 1.0 [0.0–5.0] 1.0 [0.0–2.0] 1.0 [0.0–4.0]
Suspiciousness 1.0 [0.0–5.0] 1.0 [0.0–3.0] 1.0 [0.0–3.0]
Notes. Comparisons between ex-cannabis users and respective nonuser controls for each paradigm (MMN or P50); /𝑝 < .10, ∗𝑝 < .05, ∗∗𝑝 < .001. Data
reported as median [range].
aAlcohol frequency measured as number of days per month alcohol was consumed.
bAlcohol quantity measured as number of standard drinks consumed per month.
RAVLT: Rey Auditory Verbal Learning Test; K10: Kessler Psychological Distress Scale; BDI: BeckDepression Inventory; STAI-I: State Anxiety Index State score;
STAI-II: State Anxiety Index Trait score; CAPE: Community Assessment of Psychic Experiences; SPQ: Schizotypal Personality Questionnaire.
cigarettes per day (𝑍 = −2.97,𝑝 = .01) but did not differ from
controls in quantity or frequency of alcohol use (𝑝 > .10).
Ex-users again had elevated SPQ social anxiety (𝑍 = −2.43,
𝑝 = .015) and a trend towards elevated SPQ total (𝑍 = −1.76,
𝑝 = .079) scores. None of these variables were correlated with
P50metrics and therefore nonewere included as covariates in
any further analyses (see Supplement 1).
3.3.MismatchNegativity in Ex-Users and Controls. Mismatch
negativity difference waveforms at Fz for duration and fre-
quency conditions are shown in Figure 1(a) and grand mean
ERP waveforms at Fz to the standard and deviant stimuli
are shown in Figure 1(b). Despite visible group differences
in the standard ERP around N1 (explored in Supplement
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Figure 1: (a)Mismatch negativity (MMN)waveforms at Fz displayed for each condition for ex-cannabis users (grey line) and nonuser controls
(black line). (b)Mastoid reference unsubtracted ERPwaveforms at Fz to standard (solid line) and deviant tones (dashed lines) for ex-cannabis
users (grey lines) and nonuser controls (black lines). Amplitude is shown in 𝜇V on the 𝑦-axis and time in milliseconds along the 𝑥-axis.
and controls in mean amplitude for standard ERPs over the
latency windows used for MMN peak detection.
Ex-users had visibly smaller MMN amplitudes than
controls, although this did not reach significance as a main
effect of group (𝐹(1, 34) = 1.02, 𝑝 = .32). However, there was
a main effect of condition (𝐹(2, 68) = 38.63, 𝑝 < .001) and a
significant condition by group interaction (𝐹(2, 68) = 3.34,
𝑝 = .042) (Table 3(a)). Univariate ANOVAs were used to
decompose the significant condition × group interaction and
compared ex-users and controls in each deviant condition
separately. MMN in each deviant condition revealed no effect
of group for frequency MMN (𝐹(1, 34) = 1.99, 𝑝 = .17)
or intensity MMN (𝐹 < 1.0), although groups differed at
trend level for duration MMN (𝐹(1, 34) = 2.97, 𝑝 = .09;
𝑝 = .08 with age included as a covariate (see Supplement
1)) with smaller duration MMN amplitudes in ex-users. Age
of onset of regular use, duration of regular and daily use,
and quantity and frequency of prior cannabis use were not
significantly correlated with either frequency or duration
MMN amplitude (all 𝑝 > .09). However, duration MMNwas
positively correlated with abstinence (time since regular use:
𝜌 = .65, 𝑝 = .004; time since last use: 𝜌 = .56, 𝑝 = .016), with
the pattern of results not appreciably affected by controlling
for either duration of use (partial 𝑟 = .72, 𝑝 = .001 and
𝑟 = .74, 𝑝 = .001, resp.) or age (partial 𝑟 = .63, 𝑝 = .007
and 𝑟 = .65, 𝑝 = .005, resp.) separately or combined (partial
𝑟 = .42, 𝑝 = .053 and 𝑟 = .47, 𝑝 = .032, resp.). However,
age and duration of use were not correlated with duration
MMN after controlling for time since regular use (age: partial
𝑟 = −.10, 𝑝 = .72; duration of regular use: partial 𝑟 = .05,
𝑝 = .85) or time since last use (age: partial 𝑟 = .10, 𝑝 = .69;
duration of regular use: partial 𝑟 = .13, 𝜌 = .61). These
results indicate smaller duration MMN with longer periods
of abstinence (Figure 2).
3.4. P50 Sensory Gating in Ex-Users and Controls. Grand
mean ERP waveforms at Cz to the first (S1) and second (S2)
click are presented for ex-users and controls in Figure 3, and
P50 amplitudes to S1 and S2, P50 ratio, and difference scores
in Table 3(b). Ex-users did not differ from controls in terms of
P50 difference score (𝑍 = −1.23, 𝑝 = .23). There was a trend
toward larger P50 ratios in ex-users compared to controls
(𝑍 = −1.68, 𝑝 = .097).
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Figure 2: Scatter plots showing association between duration MMN amplitude (𝜇V) and duration of abstinence since last regular cannabis
use (a) and abstinence since the last occasion of use (b).
Table 3: (a) Mean (SD) MMN amplitude (𝜇V) and latency (ms) at
Fz and (b) median [range] P50 metrics (𝜇V) at Cz for ex-cannabis








Amplitude (𝜇V) −4.60 (1.26) −5.65 (2.26)
Latency (ms) 183.9 (20.6) 183.8 (17.2)
Frequency MMN
Amplitude (𝜇V) −2.74 (1.21) −3.34 (1.35)
Latency (ms) 167.6 (22.2) 173.1 (21.7)
Intensity MMN
Amplitude (𝜇V) −3.25 (1.51) −2.92 (1.87)
Latency (ms) 153.6 (27.6) 142.4 (25.9)
(b) P50
P50 S1 amplitude 2.59 [0.36–5.14] 2.80 [0.39–9.52]
P50 S2 amplitude 1.83 [0.03–3.20] 1.27 [0.0–3.62]
P50 ratio 0.53 [0.01–4.19] 0.37 [0.0–1.41]
P50 difference score 1.66 [−1.15–3.12] 1.83 [−0.40–5.90]
In ex-users, no correlation was observed between age
of onset of regular cannabis use, quantity or frequency of
prior cannabis use per month, time since last regular use or
time since last use, and either P50 ratio or difference score
(all 𝑝 > .10). However, duration of prior regular use and
duration of prior daily use were both significantly correlated
with P50 ratio (regular use: 𝜌 = .61, 𝑝 = .007; daily use:
𝜌 = .50, 𝑝 = .033, Figure 4) and P50 difference score
(regular use: 𝜌 = −.60, 𝑝 = .008; daily use: 𝜌 = −.55, 𝑝 =
.019, Figure 4). These correlations remained significant after
controlling for the duration of abstinence since regular use in
partial correlations (P50 ratio, regular use: 𝑟 = .63, 𝑝 = .006;
daily use: 𝑟 = .57, 𝑝 = .02; P50 difference score, regular use:
𝑟 = −.64, 𝑝 = .006; daily use: 𝑟 = −.55, 𝑝 = .02). Further, time
since last regular use or time since last occasion of any usewas
not correlated with P50 metrics after controlling for duration
of regular or daily use (time since regular use: all 𝑝 > .3; time
since last use: all 𝑝 > .6).
4. Discussion
Given mounting evidence of altered MMN and P50 sensory
gating in chronic cannabis users, the current study set out to
examine the degree to which impairments in early sensory
processing might recover with abstinence from cannabis, as
a function of the duration of abstinence and history of prior
use. We report trends toward impaired sensory gating (larger
P50 ratios) and reduced duration MMN amplitude in ex-
cannabis users compared to nonuser controls. An associa-
tion between the duration of prior cannabis use and P50
metrics suggests that persistent impairments in P50 gating
may be related to prior exposure to cannabis. In contrast,
the association between MMN amplitude and duration of
abstinence was not in the expected direction, with smaller
amplitudes associated with longer abstinence. The P50 data
extend the findings of Rentzsch et al. [33] who found that
P50 sensory gating was reduced in former cannabis users
who were abstinent for at least 28 days: the ex-cannabis
users of the present study had been abstinent for a median
of 3.5 years (range of 6 weeks to 16 years). The observed
association between greater P50 impairment and duration
of prior regular and daily cannabis use in this study, and in
Rentzsch et al. [33], and no association with the duration
of abstinence, highlights the possibility that these persistent
effects may result from prolonged exposure to cannabis and
may not recover with abstinence. The findings concur also
with previous research in current cannabis users (with 12–
24 hours of abstinence to control for acute effects [31, 32, 34,
59]), implicating an association between cannabis exposure
and functioning of neuronal generators involved in sensory
gating. Unlike Rentzsch et al. [25], the current study did not
find frequency MMN amplitude to be reduced in ex-users
relative to controls.
There is increasing evidence that regular exposure to
cannabis over an extended period of time is associated with
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Figure 3: ERP waveforms to the first (S1; (a)) and second (S2; (b)) click at Cz for ex-cannabis users (grey) and nonuser controls (black).
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Figure 4: Scatter plots showing association between P50metrics and duration of regular cannabis use in years (left), duration of daily cannabis
use in months (middle), and duration of abstinence since regular use (right) for ex-cannabis users. P50 ratio shown on the top row (a) and
P50 difference score shown on the bottom row (b).
long-term users, attenuated duration MMN as well [24]. We
have argued that reduction in duration MMN may manifest
only after protracted (and especially daily) cannabis use. We
suggested that attenuated frequency MMN in short- and
long-term users may be related to altered gyrification and
cortical thinning in temporal and frontal regions observed
to be unrelated to the extent of exposure to cannabis in
users [60], while duration MMNmay be sensitive to broader
alterations to brain function associated with sound duration
processing following more prolonged exposure to cannabis
[24]. In the current study of former users, we did not observe
an association between duration of regular (or daily) cannabis
use and attenuated duration MMN, although, unexpectedly,
we found that longer durations of abstinence (both since last
regular use and since the last occasion of use) were correlated
with greater reductions in duration MMN amplitude. This
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relationship is difficult to interpret, as it is not possible
in the current sample to definitively dissociate aging from
length of abstinence (or duration of cannabis exposure).
Nevertheless, partial correlations controlling for age and for
duration of prior regular use revealed that age and duration
of prior regular use did not account for this relationship.
This association speaks to three possible hypotheses: first, that
the association between duration MMN and abstinence may
reflect accelerated aging, with persistent and nonlinear effects
beyond cessation of cannabis use in former users. Second, it is
possible that individuals who have used cannabis and subse-
quently chosen to abstain differ fundamentally from nonus-
ing individuals on a third unmeasured variable for which
duration of abstinence is acting as proxy. Nevertheless further
analysis (reported in Supplement 1) suggests that duration
of abstinence was not correlated with neuropsychological
functioning, alcohol or cigarette use, psychosis-proneness, or
prior cannabis use. A third hypothesis may therefore be that
cannabis use may have “medicated” a preexisting deficit in
former users and that this deficit is progressively unmasked
with ongoing abstinence. That duration MMN, previously
demonstrated by us to correlate with longer duration of
cannabis use (particularly daily use) [24], suggests that any
potential preexisting deficit was nevertheless exacerbated by
long-term cannabis use, perhaps interacting with the aging
process. Currently speculative, further research is required to
(dis)confirm these hypotheses.
The precise mechanisms by which prolonged exposure to
cannabis might alter the neuronal substrates which underpin
P50 indices of sensory gating remain unclear [61]. The
generators of the P50 evoked potential have been localised to
Heschl’s gyrus in the primary auditory cortex [62–64]. Less
clear are the neurobiological substrates involved in sensory
gating [63]. Currently it is thought that inhibitory inputs from
the CA3 region within the hippocampus, whilst not directly
related to P50 generation [65], may act to suppress activity
in the primary auditory cortex linked with P50 generation
to the second click [63]. Potential generators in the frontal
lobe [63] and superior temporal gyrus [66] have also been
implicated, in addition to several neurotransmitter systems
including dopaminergic, serotonergic, and glutamatergic sys-
tems [67]. A possibility, therefore, is that THC impacts upon
inhibitory inputs from the hippocampus via densely located
CB1 receptors alter an individual’s sensory gating capacity.
Furthermore, as we have suggested previously [31], there may
be a threshold of exposure associated with the duration of
regular or daily cannabis use over which impairments in
sensory gating arise and this may affect the degree to which
these deficits persist after cessation of use and similarly the
degree to which they recover. Future research might take a
longitudinal approach to further examine P50 metrics before
and after cessation of cannabis use, to assess potential changes
over time within the same individuals.
There are a number of limitations in the current study
which may be addressed by future work. First, as a cross-
sectional and naturalistic study we relied on participant self-
report for the duration of abstinence and history of cannabis
use.The current study set out to examineMMNand P50met-
rics as a function of a broad duration of abstinence and prior
use, and for this reason it was not possible to supervise absti-
nence in a way consistent with protocols employed in prior
research examining short durations of abstinence (e.g., 28
days) [68]. As such, the duration of abstinence in this sample
was broadly distributed, but more than half had abstained for
the period between 6 weeks and 5 years, which should have
captured any evidence for either abrupt or gradual recovery
during the early period following cessation of use, as well as
enabling detection of evidence for any gradual recovery that
might require a significant period of abstinence. No evidence
for any such patterns was observed; however, this requires
replication in a larger sample of ex-cannabis users. Second,
despite our observation that altered P50 metrics were signif-
icantly associated with the duration of exposure to cannabis,
the extent to which these alterations to brain function are
present prior to cannabis exposure remains unknown and
may be answered by longitudinal studies.Third, we acknowl-
edge an argument that while education and IQ did not corre-
late with our ERPmeasures and were therefore inappropriate
as covariates in our analyses, the group differences on these
measures may point to differences in cognitive function that
could affect potential recovery or even predate cannabis use.
This cannot be easily ruled out. Nevertheless, ex-cannabis
users in the current study did not differ fromnonuser controls
in terms of verbal learning and memory performance, and
there were very few differences between groups in terms
of psychological wellbeing, including psychosis-proneness.
Future research should examine the functional significance
of these apparently persistent alterations in sensory gating
in long-term former cannabis users and the extent to which
theymay impact upon functioning in daily life and/or predate
cannabis use affecting recovery of function. We acknowl-
edge that the sample size of the ex-user group was small.
Nevertheless, the sample represents a unique population of
clean cannabis users (unconfounded by other drug use or
psychopathology) with long histories of prior cannabis use
and with prolonged abstinence, a sample that is difficult to
recruit and is rarely reported in the literature.
5. Conclusions
In summary, the trend level pattern of results of the current
study suggests that cannabis-related alterations to MMN
and P50 may not fully recover following cessation of long-
term cannabis use. Instead, the current data suggest that (i)
prolonged exposure to cannabis alters P50 sensory gating and
these alterations may persist beyond cessation of use and (ii)
MMN amplitude may reduce further with increasing absti-
nence.The results raise the possibility of persistent alterations
to the regulatory role of the endocannabinoid systemonbrain
function, affecting the brain’s ability to regulate its response
to incoming stimuli or to filter irrelevant information. These
results require replication in future studies of brain functional
plasticity-related recovery in abstinent cannabis users.
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[23] A. E. Şevik, A. E. A. Yagcioglu, S. Yagcioglu, S. Karahan, N.
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